戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 .5 months; 95% CI, 19.9-24.0 months) but not multiagent AC (19.1 months; 95% CI, 17.5-21.1 months) co
2  cohort was subdivided into single-agent and multiagent AC treatment.
3                                              Multiagent activity is commonplace in everyday life and
4                                 The use of a multiagent algorithm was effective for the initial conve
5   The modeling approach we use is a combined multiagent and classifier systems simulation.
6 twork (social and knowledge approach) with a multiagent approach to effect more realistic behavior.
7 ct of n-3 FAs in breast cancer, as part of a multiagent approach under rigorously controlled conditio
8 he power of systems approaches for analyzing multiagent behavioral dynamics.
9                                   Randomized multiagent chemoradiotherapeutic trials have been approa
10                                   Concurrent multiagent chemoradiotherapy can result in organ preserv
11        Patients then received a postsurgical multiagent chemotherapeutic regimen that consisted of hi
12                                              Multiagent chemotherapeutic regimens in concert with ade
13                                              Multiagent, chemotherapeutic regimens for children have
14 rates are poor after standard doxorubicin or multiagent chemotherapies.
15 ficantly different 5-yr survival rates after multiagent chemotherapy (62% vs. 26%; P < or = 0.0051),
16 e substantially improved when RT is added to multiagent chemotherapy (IRS-I and II).
17 les of blinatumomab (n = 105) or 2 cycles of multiagent chemotherapy (n = 103), each followed by tran
18 ry ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years t
19 lder and unfit patients can receive suitable multiagent chemotherapy and be allocated to HCT based on
20  Thus, thalidomide given in combination with multiagent chemotherapy and dexamethasone is associated
21                      All patients were given multiagent chemotherapy and most received irradiation (X
22 l removal if resectable, in combination with multiagent chemotherapy and possibly radiation therapy,
23 hat three different approaches of concurrent multiagent chemotherapy and radiation were feasible and
24 ad received at least a lobectomy followed by multiagent chemotherapy and radiotherapy; cohort one inc
25 improved cure fraction by the combination of multiagent chemotherapy and surgery, although we found n
26 evel of myeloma-propagating cells to survive multiagent chemotherapy and to result in relapse.
27 -cell lung cancer who received postoperative multiagent chemotherapy between 18 and 127 days after re
28 tients with SCLC who received platinum-based multiagent chemotherapy between 2000 and 2020 for ES-SCL
29  conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater e
30                                  Advances in multiagent chemotherapy have led to recent improvements
31                Use of consolidative RT after multiagent chemotherapy in DLBCL is decreasing in the mo
32 Foundation studying radiation and concurrent multiagent chemotherapy in patients with locoregionally
33                                              Multiagent chemotherapy is standard of care for both ped
34 it-course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse
35 rs associated with pCR included preoperative multiagent chemotherapy other than (m)FOLFIRINOX ([modif
36                          In the context of a multiagent chemotherapy protocol comprising high-dose me
37 oma have remained dismal despite intensified multiagent chemotherapy protocols.
38  or less, and received at least one previous multiagent chemotherapy regimen.
39 en given a previously established first-line multiagent chemotherapy regimen; or had incomplete data
40       Second-line therapy typically includes multiagent chemotherapy regimens followed by autologous
41 ing plan regimens, and within the context of multiagent chemotherapy regimens that include alkylating
42 ologous stem cell transplant or two previous multiagent chemotherapy regimens, and for patients with
43 nced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including FOLFIRINOX,
44 c leukemia (ALL) are cured with contemporary multiagent chemotherapy regimens.
45  with short durations of high dose-intensity multiagent chemotherapy regimens.
46 r relapse-free survival despite risk-adapted multiagent chemotherapy regimens.
47 % improved to 65% to 70% after the advent of multiagent chemotherapy regimens.
48                                      Primary multiagent chemotherapy should only be given to patients
49      Both groups were more likely to receive multiagent chemotherapy than were older patients (patien
50 ive disease continued to receive 44 weeks of multiagent chemotherapy that incorporated the assigned i
51 ance to single-agent treatments and required multiagent chemotherapy to achieve remission.
52  with the remaining patients requiring toxic multiagent chemotherapy to attain remission.
53               The median TTNT for single- or multiagent chemotherapy was only 3.9 months (95% confide
54 enty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with P
55  adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem cell rescue.
56  adjuvant chemotherapy followed by high-dose multiagent chemotherapy with stem-cell rescue, we estima
57 e directly compared with a previous study of multiagent chemotherapy without irradiation (Pediatric O
58 cellent prognosis when treated with adjuvant multiagent chemotherapy without RT.
59                           Methotrexate-based multiagent chemotherapy without WBRT is associated with
60                Forty-eight patients received multiagent chemotherapy, and 118 were treated with hormo
61  severe granulocytopenia following intensive multiagent chemotherapy, but is associated with worsened
62    After surgery, they received 2 courses of multiagent chemotherapy, followed by 3 courses of high-d
63 ents have a complete therapeutic response to multiagent chemotherapy, half will relapse, indicating t
64 ge regimens, including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxy
65       Current treatment standard is based on multiagent chemotherapy, including anthracycline and mon
66 9), and ovarian (n= 143) cancer treated with multiagent chemotherapy, of which 233 patients were from
67 n, lower Charlson score, smaller tumor size, multiagent chemotherapy, resection with at least a lobec
68 rlson comorbidity score, smaller tumor size, multiagent chemotherapy, resection with at least a lobec
69  clinical course was aggressive, and despite multiagent chemotherapy, the median survival duration wa
70 mphoblasts isolated from a patient receiving multiagent chemotherapy, this site-specific double-stran
71  microenvironment influences the response to multiagent chemotherapy, we found that stromal Nf1 statu
72                  He completed treatment with multiagent chemotherapy-carboplatin, vincristine, temozo
73 ents have complete remission with subsequent multiagent chemotherapy.
74 ghly curable in younger patients who receive multiagent chemotherapy.
75 ts when used up front either with or without multiagent chemotherapy.
76 of 5 or 6 are likely to benefit from upfront multiagent chemotherapy.
77 own to be curable with radiation therapy and multiagent chemotherapy.
78  the induction and intensification phases of multiagent chemotherapy.
79 n 50% of the patients are cured with current multiagent chemotherapy.
80                    Toxicity was greater with multiagent chemotherapy.
81  (95% CI, 0.9-1.3 years) for those receiving multiagent chemotherapy.
82                All but two patients received multiagent chemotherapy.
83                             Therapy included multiagent chemotherapy; local control was achieved by r
84                               We report on a multiagent computational model of this society that clos
85 roups, organizations, and societies by using multiagent computational models composed of collections
86                  In younger adults with AML, multiagent consolidation using mitoxantrone and amsacrin
87 th three cycles of 18 g/m(2) (3x HD-AraC) or multiagent consolidation with two cycles of mitoxantrone
88 s promise for applications requiring dynamic multiagent control over DNA-based devices, offering a ve
89 g dynamical motor primitives (DMPs) of human multiagent coordination that not only capture the behavi
90 ounts of input data and to engage in complex multiagent dialogues.
91 gh-throughput combination drug screening and multiagent drug delivery that maximizes the therapeutic
92                         Last, we demonstrate multiagent formation control, with flies alternating bet
93 ns of expert and novice players completing a multiagent herding task.
94 erapy using total body irradiation (TBI) and multiagent, high-dose chemotherapy.
95       This approach was investigated using a multiagent imaging protocol for which patients were imag
96 ghly variable unmanipulated donor grafts and multiagent immune suppression.
97 one-third of patients with DLBCL, first-line multiagent immunochemotherapy fails to produce a durable
98                     Prompt administration of multiagent immunochemotherapy regimens is associated wit
99 lopment of alloreactivity despite the use of multiagent immunoprophylaxis.
100 ival and extraocular tissue transplantation, multiagent immunosuppressant therapy, and bioartificial
101                                     Lifelong multiagent immunosuppression is necessary to control deb
102 atients were assigned to receive 20 weeks of multiagent induction chemotherapy and 4 weeks of radioth
103  or equal to 10(-3) at the end of 4 weeks of multiagent induction chemotherapy now receive intensifie
104 th inoperable LAPC found that A-RT following multiagent induction therapy for LAPC was associated wit
105 ium, yielding an online method of predicting multiagent interactions given their SVOs.
106 strating the usefulness and complications of multiagent intravitreal chemotherapy is necessary for su
107        Based on these findings, we developed multiagent lipid nanoparticle formulations of these drug
108 nd neoadjuvant/adjuvant single-agent (SA) or multiagent (MA) chemotherapy independent of RT.
109                                            A multiagent mobility simulation model was built to simula
110                                            A multiagent modeling approach enables the quantification
111             We present a pipeline comprising multiagent models acting as forward solvers for systems
112  field control (MFC) are critical classes of multiagent models for the efficient analysis of massive
113 strated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 imm
114                                        Newer multiagent NAC regimens have resulted in improved clinic
115 ts with invasive breast cancer who underwent multiagent NACT with (n = 49) or without (n = 13) taxane
116 al of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a pr
117                        This study shows that multiagent PET is feasible and yields unique and potenti
118                            Total duration of multiagent protocol chemotherapy ranging from 2.5 to 3.5
119 oma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy
120 All patients were refractory to at least one multiagent regimen or had relapsed after achieving a com
121 ogic malignancies both as monotherapy and in multiagent regimens in relapsed/refractory disease as we
122  administered in the setting of hepatectomy, multiagent regimens produced a higher cure rate than sin
123  of action of the drugs used and look at the multiagent regimens recommended for use during pregnancy
124  receive systemic chemotherapy, particularly multiagent regimens, at all stages relative to those wit
125  in patients refractory to other single- and multiagent reinduction therapies.
126 ing, we investigate a class of discrete-time multiagent reinforcement learning (MARL) dynamics in pop
127          These elements are well captured in multiagent reinforcement learning (MARL), which has rece
128 results highlight the benefit of employing a multiagent reinforcement learning computational model fo
129 hese results indicate the great potential of multiagent reinforcement learning for artificial intelli
130                 Here, we use game theory and multiagent reinforcement learning to investigate how und
131                                  Here we use multiagent reinforcement learning to investigate the lea
132   Our results highlight the benefit of using multiagent reinforcement learning to model theoretically
133 in films capable of administering sustained, multiagent release profiles.
134  release as well as both parallel and serial multiagent release.
135 sical Hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous h
136 all center around the issue of learning in a multiagent setting, and specifically the question of whe
137               We demonstrate our approach on multiagent settings involving players that are partially
138         Decision making under uncertainty in multiagent settings is of increasing interest in decisio
139                  The adoption of aggressive, multiagent, short-course therapy has markedly improved o
140                                              Multiagent simulation is discussed as a way to link cult
141                            Here we resort to multiagent simulations, where a population of individual
142 phocytes, stroma, and necrosis to generate a multiagent spatial model.
143                  The concerted effort of the multiagent system allows for addressing complex material
144 1 evaluated 735 generated suggestions from a multiagent system developed for optimizing order sets, w
145  The information economy will be the largest multiagent system ever conceived and an integral part of
146       In this cohort study of an LLM-powered multiagent system for optimizing order sets, leveraging
147         DESIGN, SETTING, AND PARTICIPANTS: A multiagent system was developed and evaluated between Ja
148                        All patients received multiagent systemic chemotherapy and whole-brain irradia
149 n the National Cancer Data Base who received multiagent systemic chemotherapy combined with high-inte
150 administered in association with concomitant multiagent systemic chemotherapy to children younger tha
151 lapsed or refractory DLBCL after two or more multiagent systemic treatments, who had measurable disea
152 r optimizing order sets, leveraging LLMs and multiagent systems provided a scalable approach.
153 ol scheme for a class of nonaffine nonlinear multiagent systems.
154 one microenvironment and several single- and multiagent targeted approaches to the treatment of advan
155 d understanding human decision-making during multiagent task performance.
156 ether DMPs can be used to model more complex multiagent task scenarios.
157  PEG-ASP is feasible as part of an intensive multiagent therapeutic regimen in adult acute lymphoblas
158 nd lead to the development of more effective multiagent therapies.
159 trol 232 +/- 30), while animals treated with multiagent therapy had an average nodule count of 11 +/-
160 tion factors are unknown, some centres offer multiagent therapy upfront, resulting in overtreatment o
161 atients most likely to benefit from selected multiagent therapy.
162       In this paper, we study the problem of multiagent time-series imputation in the context of huma
163 r efficacy was observed with single-agent or multiagent treatment.
164 patectomy, immunization with single-agent or multiagent vaccine therapy appears equivalent.
165               In the setting of hepatectomy, multiagent vaccine therapy offers an advantage over sing
166 ent) or a combination of RANTES/B7.1/GM-CSF (multiagent) was tested.
167                                           In multiagent worlds, several decision-making individuals i

 
Page Top